Cilostazol Activates Function of Bone Marrow-Derived Endothelial Progenitor Cell for Re-endothelialization in a Carotid Balloon Injury Model
2011

Cilostazol and Its Role in Blood Vessel Healing

Sample size: 14 publication Evidence: high

Author Information

Author(s): Kawabe-Yako Rie, Masaaki Ii, Masuo Osamu, Asahara Takayuki, Itakura Toru

Primary Institution: Group of Vascular Regeneration Research, Institute of Biomedical Research and Innovation, RIKEN Center for Developmental Biology, Kobe, Japan

Hypothesis

Cilostazol might accelerate re-endothelialization with endothelial progenitor cells (EPCs).

Conclusion

Cilostazol promotes EPC mobilization and recruitment to sites of arterial injury, inhibiting neointima formation and accelerating re-endothelialization.

Supporting Evidence

  • Cilostazol treatment resulted in a significant increase in the re-endothelialized area compared to the control group.
  • Cilostazol significantly reduced neointimal thickening at 2 and 4 weeks after carotid injury.
  • The number of circulating EPCs was significantly higher in the cilostazol group compared to the control group.

Takeaway

Cilostazol helps heal injured blood vessels by making special cells called endothelial progenitor cells work better and move to the injury site.

Methodology

The study involved balloon carotid denudation in male Sprague-Dawley rats, with one group receiving cilostazol mixed feed and the other a normal diet.

Participant Demographics

Male Sprague-Dawley rats, aged 16 to 19 weeks.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0024646

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication